{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:01:20Z","timestamp":1784192480324,"version":"3.55.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The COVID-19 pandemic has led to a significant increase in the immunosuppressed population worldwide due to the disease pathology and extensive use of corticosteroids. This has subsequently increased the risk of opportunistic parasitic infections such as Toxoplasma gondii, Strongyloides stercoralis and other parasites in these patients. The reactivation of such parasites may remain unnoticed due to overlapping symptoms, the difficulty of diagnosis and lack of guidelines for opportunistic parasitic infections in COVID-19 management. Therefore, recommendations for systematic screening of high-risk patients in endemic regions and active research and surveillance to estimate the impact of these infections are required in COVID-19 policy guidelines.<\/jats:p>","DOI":"10.1093\/trstmh\/trab142","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T04:40:45Z","timestamp":1630730445000},"page":"1345-1347","source":"Crossref","is-referenced-by-count":8,"title":["Considering opportunistic parasitic infections in COVID-19 policies and recommendations"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-6167","authenticated-orcid":false,"given":"Abhishek","family":"Mewara","sequence":"first","affiliation":[{"name":"Department of Medical Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeru","family":"Sahni","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Jain","sequence":"additional","affiliation":[{"name":"Anesthesiology Institute, Cleveland Clinic, Abu Dhabi, PO Box 112412, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2021110203045882300_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2021110203045882300_bib2","article-title":"Therapeutics and COVID-19","author":"World Health Organization"},{"issue":"10285","key":"2021110203045882300_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2021110203045882300_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","author":"Osuchowski","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"6","key":"2021110203045882300_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41577-020-0330-5","article-title":"Will helminth co-infection modulate COVID-19 severity in endemic regions?","volume":"20","author":"Bradbury","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2021110203045882300_bib6","doi-asserted-by":"crossref","first-page":"624483","DOI":"10.3389\/fcimb.2021.624483","article-title":"T-helper cell subset response is a determining factor in COVID-19 progression","volume":"11","author":"Gil-Etayo","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"2021110203045882300_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","author":"Robert-Gangneux","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021110203045882300_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11481-021-09997-0","article-title":"The symptoms and clinical manifestations observed in COVID-19 patients\/long COVID-19 symptoms that parallel Toxoplasma gondii infections","volume":"16","author":"Roe","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"issue":"7","key":"2021110203045882300_bib9","doi-asserted-by":"crossref","first-page":"e2288","DOI":"10.1371\/journal.pntd.0002288","article-title":"Strongyloides stercoralis: global distribution and risk factors","volume":"7","author":"Sch\u00e4r","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"2021110203045882300_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2020.13170","article-title":"COVID-19 and dexamethasone: a potential strategy to avoid steroid-related Strongyloides hyperinfection","volume":"324","author":"Stauffer","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2021110203045882300_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13099-021-00427-3","article-title":"Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections","volume":"13","author":"Abdel-Hamed","year":"2021","journal-title":"Gut Pathog"},{"issue":"8","key":"2021110203045882300_bib12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciaa933","article-title":"Predicted impact of COVID-19 on neglected tropical disease programs and the opportunity for innovation","volume":"72","author":"Toor","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/11\/1345\/41042573\/trab142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/11\/1345\/41042573\/trab142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T03:05:10Z","timestamp":1635822310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/115\/11\/1345\/6363886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":12,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trab142","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,9,3]]}}}